Charles Schwab Trust CO Bristol Myers Squibb CO Transaction History

Charles Schwab Trust CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 09, 2024	BUY	$48.48 - $57.85 $1,696 - $2,024	35 Added 0.7%	5,021 $257,000
Q3 2023 Oct 19, 2023	SELL	$57.89 - $64.73 $3,878 - $4,336	-67 Reduced 1.33%	4,986 $289,000
Q2 2023 Jul 24, 2023	SELL	$63.71 - $70.74 $155,006 - $172,110	-2,433 Reduced 32.5%	5,053 $323,000
Q1 2023 Apr 10, 2023	SELL	$65.71 - $74.53 $220,982 - $250,644	-3,363 Reduced 31.0%	7,486 $518,000
Q2 2022 Jul 22, 2022	BUY	$72.62 - $79.98 $10,675 - $11,757	147 Added 1.37%	10,849 $835,000
Q1 2022 Apr 14, 2022	SELL	$61.48 - $73.72 $189,358 - $227,057	-3,080 Reduced 22.35%	10,702 $782,000
Q4 2021 Jan 14, 2022	SELL	$53.63 - $62.52 $16,249 - $18,943	-303 Reduced 2.15%	13,782 $859,000
Q3 2021 Oct 08, 2021	BUY	$59.17 - $69.31 $17,928 - $21,000	303 Added 2.2%	14,085 $833,000
Q2 2021 Aug 04, 2021	SELL	$61.91 - $67.42 $3,962 - $4,314	-64 Reduced 0.46%	13,782 $921,000
Q1 2021 Apr 14, 2021	SELL	$59.34 - $66.74 $480,001 - $539,859	-8,089 Reduced 36.88%	13,846 $871,000
Q4 2020 Jan 14, 2021	BUY	$57.74 - $65.43 $473,756 - $536,853	8,205 Added 59.76%	21,935 $1.36 Million
Q3 2020 Oct 30, 2020	SELL	$57.43 - $63.64 $36,697 - $40,665	-639 Reduced 4.45%	13,730 $828,000
Q2 2020 Jul 28, 2020	BUY	$54.82 - $64.09 $45,445 - $53,130	829 Added 6.12%	14,369 $843,000
Q1 2020 Apr 09, 2020	SELL	$46.4 - $67.43 $8,120 - $11,800	-175 Reduced 1.28%	13,540 $755,000
Q4 2019 Jan 29, 2020	BUY	$49.21 - $64.19 $251,315 - $327,818	5,107 Added 59.33%	13,715 $880,000
Q3 2019 Nov 15, 2019	BUY	$42.77 - $50.71 $368,164 - $436,511	8,608 New	8,608 $436,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Charles Schwab Trust CO, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Trust CO with notifications on news.